Fractyl Health, Inc. Common Stock (GUTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fractyl Health, Inc. Common Stock (GUTS) has a cash flow conversion efficiency ratio of 9.550x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.90 Million) by net assets ($-1.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GUTS stock market capitalisation for the company's overall valuation and market capitalisation.
Fractyl Health, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Fractyl Health, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fractyl Health, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fractyl Health, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore GUTS cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tong Herr Resources Bhd
KLSE:5010
|
0.126x |
|
Alkim Alkali Kimya AS
IS:ALKIM
|
0.070x |
|
Royce Global Value Trust Inc
NYSE:RGT
|
0.001x |
|
PannErgy Nyrt.
F:PPL
|
0.168x |
|
Tat Gida Sanayi AS
IS:TATGD
|
0.249x |
|
GENOR BIOPHARMA DL-00002
F:67N0
|
N/A |
|
Freetrailer Group A/S
ST:FREETR
|
-0.022x |
|
CAB Cakaran Corporation Bhd
KLSE:7174
|
0.032x |
Annual Cash Flow Conversion Efficiency for Fractyl Health, Inc. Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Fractyl Health, Inc. Common Stock from 2019 to 2025. View Fractyl Health, Inc. Common Stock share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $9.46 Million | $-90.33 Million | -9.550x | -314.31% |
| 2024-09-30 | $28.42 Million | $-65.52 Million | -2.305x | -1849.78% |
| 2023-09-30 | $-325.06 Million | $-42.82 Million | 0.132x | -28.12% |
| 2022-09-30 | $-252.32 Million | $-46.24 Million | 0.183x | +14.65% |
| 2021-09-30 | $-209.32 Million | $-33.46 Million | 0.160x | +107.69% |
| 2020-09-30 | $14.95 Million | $-31.07 Million | -2.078x | -1179.23% |
| 2019-09-30 | $-144.00 Million | $-27.73 Million | 0.193x | -- |
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a nove… Read more